Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special Reports
Special Reports
The top 10 drugs losing US exclusivity in 2026
While megablockbusters naturally command significant attention, Fierce takes a chance each year to look at older medicines nearing their tumble over the patent cliff.
Eric Sagonowsky
,
Fraiser Kansteiner
,
Kevin Dunleavy
,
Zoey Becker
Mar 16, 2026 3:00am
Top 10 most anticipated drug launches of 2026
Feb 2, 2026 3:00am
2025's top biopharma M&A deals
Jan 12, 2026 3:00am
2025 approvals: Biopharma delivered 55 new drugs, biologics
Jan 5, 2026 3:00am
2025's Fiercest Women in Life Sciences
Nov 17, 2025 3:00am
Fierce 50 of 2025
Sep 2, 2025 4:30am